Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288963 · ClinicalTrials.gov registry record
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
A clinical trial, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 153
- Enrollment target
NCT01288963 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 153 participants.
The verdict
NCT01288963 has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 153 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.
Interventions
- DRUG IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2010-02 |
| Est. Completion | 2020-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01288963
The ClinicalTrials.gov registry entry for NCT01288963 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IL-2 is the first listed.
NCT01288963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01288963 about?
NCT01288963 is a clinical study titled "IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma". The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor sam...
What is the current status of trial NCT01288963?
This trial is currently completed. The enrollment target is 153 participants. The study started on 2010-02. Estimated completion is 2020-12.
What interventions are being tested in trial NCT01288963?
The interventions under investigation include: IL-2 (DRUG).
Who is sponsoring clinical trial NCT01288963?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.